Identification of Crucial Genes and Biological Pathways in Lung Adenocarcinoma by Network Pharmacology, Molecular Docking, and Simulation Studies

Why It Matters

The work identifies a natural compound that directly engages a central oncogenic driver, offering a cost‑effective, low‑toxicity avenue for lung cancer treatment. Translating these computational insights could diversify therapeutic options in a field plagued by resistance.

Key Takeaways

• Four Pleurotus compounds meet drug-likeness criteria.
• 226 lung adenocarcinoma targets overlap with mushroom compounds.
• AKT1 binds isosorbide with −9.6 kcal/mol affinity.
• Molecular dynamics shows stable AKT1‑isosorbide complex.
• Hub genes AKT1, HSP90AA1, IL6, CASP3, SRC identified.

Pulse Analysis

Computational drug discovery is reshaping oncology by rapidly screening vast chemical spaces without the expense of early‑stage laboratory work. In the case of lung adenocarcinoma, a disease responsible for a sizable share of cancer deaths, integrating network pharmacology with docking and dynamics simulations enables researchers to pinpoint which natural molecules intersect with disease‑relevant pathways. By mapping 609 predicted targets of Pleurotus membranaceus compounds against over 3,000 LUAD‑associated genes, the study isolated a focused set of 226 intersecting proteins, streamlining the hunt for actionable leads.

Among the intersecting proteins, AKT1 emerged as a high‑value target due to its pivotal role in cell survival, proliferation, and metabolism. The docking score of –9.6 kcal/mol for isosorbide suggests a strong thermodynamic fit, while molecular dynamics confirmed a stable binding pose with a free‑energy estimate of –193.8 kJ/mol. Such robust interaction profiles, coupled with the identification of additional hub genes like HSP90AA1 and IL6, point to a multi‑targeted mechanism that could simultaneously trigger apoptosis, curb angiogenesis, and impede metastasis—key challenges in current LUAD therapy.

The next logical step is experimental validation, beginning with in‑vitro assays to verify cytotoxicity and pathway modulation, followed by animal models to assess pharmacokinetics and safety. If these phases confirm the computational predictions, isosorbide‑based formulations could enter clinical pipelines as adjuncts to existing regimens, potentially lowering dosage requirements and side‑effect burdens. Moreover, this research underscores the broader potential of edible mushrooms as reservoirs of drug‑like molecules, encouraging further exploration of natural product libraries in precision oncology.